Adagio Therapeutics Competitors and Similar CompaniesClear all

Adagio Therapeutics's competitors and similar companies include Atea Pharmaceuticals, Genentech, Cipla and EMS Pharma.

	Adagio Therapeutics Adagio is a clinical-stage biopharmaceutical company focusing on the discovery and development of antibody-based solutions for infectious diseases with pandemic potential.	Atea Pharmaceuticals Atea Pharmaceuticals is a biopharmaceutical company specializing in oral direct-acting antiviral therapies.	Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.	Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.	EMS Pharma EMS Pharma is a company that specializes in the research, development, and manufacturing of pharmaceuticals.
Founding Date	Founding Date 2020	Founding Date 2014	Founding Date 1976	Founding Date 1935	Founding Date 1964
Type	Type Public	Type Public	Type Subsidiary	Type Public	Type Private
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Waltham, US HQ	Locations Boston, US HQ Boston, US	Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more	Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more	Locations BR HQ
Employees	Employees 74	Employees 552% decrease	Employees 18,077	Employees 27,764	Employees 12,7441% increase
Valuation ($)	Valuation ($) 516.2 m	Valuation ($) 290.4 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $53.4m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ₹277.1b (FY, 2026)	Revenue (est.) N/A
Net income	Net income ($52.5m) (FY, 2025)	Net income ($158.3m) (FY, 2025)	Net income N/A	Net income ₹38.7b (FY, 2026)	Net income N/A
Operating ⚠
Phase I Trials Products	Phase I Trials Products N/A	Phase I Trials Products 2 (Q2, 2020)	Phase I Trials Products 28 (Jul, 2025)	Phase I Trials Products N/A	Phase I Trials Products N/A
Phase II Trials Products	Phase II Trials Products N/A	Phase II Trials Products 2 (Q2, 2020)	Phase II Trials Products 19 (Jul, 2025)	Phase II Trials Products N/A	Phase II Trials Products N/A